Brainstorm Cell Therapeutics Inc.
BCLI
$0.61
$0.000.51%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.60% | -28.53% | -26.71% | -34.14% | -13.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.11% | -26.98% | -34.40% | -45.46% | -38.25% |
| Operating Income | 18.11% | 26.98% | 34.40% | 45.46% | 38.25% |
| Income Before Tax | 23.77% | 10.18% | 28.63% | 32.39% | 14.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.77% | 10.18% | 28.63% | 32.39% | 14.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.77% | 10.18% | 28.63% | 32.39% | 14.45% |
| EBIT | 18.11% | 26.98% | 34.40% | 45.46% | 38.25% |
| EBITDA | 18.09% | 27.14% | 34.70% | 45.91% | 38.65% |
| EPS Basic | 56.59% | 45.89% | 58.32% | 61.53% | 47.23% |
| Normalized Basic EPS | 56.59% | 45.89% | 58.32% | 61.52% | 47.23% |
| EPS Diluted | 56.59% | 45.89% | 58.32% | 61.74% | 47.50% |
| Normalized Diluted EPS | 56.59% | 45.89% | 58.32% | 61.52% | 47.23% |
| Average Basic Shares Outstanding | 77.88% | 68.16% | 65.62% | 74.91% | 69.82% |
| Average Diluted Shares Outstanding | 77.88% | 68.16% | 65.62% | 74.91% | 69.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |